Measurements
At least 3 months after an acute episode, pulmonary hemodynamics, cardiac output (using thermodilution technique) and blood gases were measured in the supine position while breathing normally. The cardiac index was calculated as cardiac output divided by body surface area. Pulmonary vascular resistance (PVR) was calculated conventionally as the ratio of the difference between mean Ppa and pulmonary wedge pressure to cardiac output. Cardiorespiratory variables were also measured after surgery. To evaluate the effectiveness of surgery, the % decrease in PVR was calculated using [preoperative PVR -postoperative PVR] ×100 (%)/preoperative PVR.
HLA Typing
HLA typing was analyzed in 126 patients. Serological HLA typing of A and B antigens was done using a standard microcytotoxicity test. 12 Genomic DNA was obtained from peripheral blood leukocytes using a QIAamp DNA blood minikit (Qiagen). DNA typing of HLA-B and -DPB1 genes was performed using a RELI-typing kit (Dynal) and/or using SSO probes as previously reported. 13, 14 
Assessment of Central Extent of Thrombi
Using the Bergin's method, central arteries were defined as vessels proximal to the segmental branches and were divided into 4 portions. These portions included the right and left main pulmonary arteries proximal to the upper lobe branches and the right and left descending portions of the central arteries between the upper lobes and the segmental branches. The central disease score was quantified by adding up the number of abnormal central portions in each patient up to a maximum score of 4. 15 Two investigators retrospectively calculated the scores independently by workstation, and if the score differed, it was changed to either one score up or down by consensual agreement of the 2 investigators.
During the operation, thromboembolic disease was visualized and each patient was classified into one of 4 groups as reported by Thistlethwaite (intraoperative classification): type 1, fresh thrombus in the main-lobar pulmonary arteries; type 2, intimal thickening and fibrosis proximal to the segmental arteries; type 3, disease within distal segmental arteries only; and type 4, distal arteriolar vasculopathy without visible thromboembolic disease. 16 
Pulmonary Endarterectomy
The selection criteria for pulmonary thromboendarterectomy were slightly modified from those defined by Moser. 17 Our criteria were: (1) mean Ppa >30 mmHg, resulting in calculated PVR >300 dynes·s·cm -5 even after oral anticoagulant therapy for >6 months; (2) WHO functional class ≥3; (3) thrombi defined as accessible to current surgical techniques (presence at main, lobar, segmental arteries); and (4) absence of severe associated disease. 4, 18 Although we have used a lateral thoracotomy in 16 previous cases, since 1990 we used median sternotomy with the application of deep hypothermia and circulatory arrest in 62 cases. 4, 19 The Human Subject Committee of Chiba University approved the study, written informed consent was obtained from all patients and the study protocol for HLA typing was approved by the Research Ethics Committee of Chiba University School of Medicine.
Clinical characteristics were compared between males and females in all patients, and in patients with or without HLA-B*5201, respectively.
Statistical Analysis
Comparison of males and females was performed using unpaired Student's t-test when data were continuous variables, and by chi-square test or Mann-Whitney test when data were categorical, where appropriate. We performed a 2-way factorial analysis of variance (ANOVA) for parametric data and multiple regression analysis for categorized data, using gender and HLA-B*5201 as independent variables, and other clinical parameters as dependent variables. A p-value<0.05 was considered significant.
Results

Patient Characteristics
Characteristics of the patients are shown in Table 1 . There were more female (n=103) than male patients (n=47). Age at catheterization varied from 18 to 78 years, with a mean ± SD of 52.8±12.4. Sixty-eight patients (45.3%) had a history of acute embolic episodes. Fifty-eight patients (38.7%) had a history of DVT. Forty-seven patients (31.3%) revealed abnormalities in the screening for coagulopathy. Thirty-seven patients (24.7%) were diagnosed with antiphospholipid syndrome. Mean Ppa, cardiac index, PVR and PaO2 were 44.2±11.1 mmHg, 2.54±0.63 L·min -1 ·m -2 , 827± 382 dynes· s· cm -5 and 58.6±9.8 Torr, respectively. The patients were classified as WHO functional class I (n=2), class II (n=37), class III (n=97) and class IV (n=14).
Comparison of Clinical Characteristics Between Males and Females
As shown in mean right atrial pressure (Pra) was significantly lower in females than in males (4.3±3.5 vs 7.1±5.5 mmHg, p= 0.0002). However, PaO2 in females was significantly lower than in males (56.4±9.8 vs 61.7±9.8 Torr, p=0.005). With regard to the WHO functional classification, there was no significant difference between females and males.
Central disease score in females was significantly lower than in males, indicating a peripheral type (1.09±1.01 vs 1.83±1.27, p=0.0002). With regard to intra-operative classification, female patients showed significantly more nontype 1 disease compared with male patients (38.3 vs 9.7%, p=0.005).
Surgical Outcome and Gender
Although there was no significant difference in mortality between males and females, postoperative PVR in females was significantly higher than in males (406±282 vs 257± 119 dynes·s·cm -5 , p=0.02), and the percentage decrease in PVR in females was significantly less than in males (51.9± 25.4 vs 65.2±21.4%, p=0.04) ( Table 3) .
Association With Gender Differences in Clinical Characteristics and HLA-B*5201
As shown in Table 4 , in HLA-B*5201-positive patients, females showed less embolic episodes (27.0 vs 80.0%, p=0.002). The cardiac index in females was significantly higher than in males (2.77±0.61 vs 2.23±0.38 L·min -1 ·m -2 , p=0.001), and mean Pra in females was significantly lower than in males (3.9±3.7 vs 8.2±5.9 mmHg, p=0.0006). The surgical mortality was significantly lower in females than in males (0 vs 40%, p=0.0098).
In contrast, as shown in Table 5 , in HLA-B*5201-negative patients, female CTEPH patients had less embolic episodes (40.4 vs 66.7%, p=0.03), lower central disease score (0.93±0.98 vs 2.04±1.32, p<0.0001) and more non-type 1 disease (48.0 vs 0.0%, p=0.0005), indicating the peripheral type of emboli. As a result, female patients showed higher postoperative PVR (405±303 vs 234±115 dynes· s· cm -5 , p=0.05) and a modest percentage decrease in PVR compared with males (55.6±21.3 vs 69.9±18.3%, p=0.04).
Two-way factorial ANOVA and multiple regression analysis revealed that the HLA-B*5201-positive type was significantly correlated with the absence of DVT (p=0.005), but female gender was not correlated with the absence of DVT (p=0.06). HLA-B*5201 did not show any correlation with any other clinical parameters (p>0.10). In contrast, female gender correlated with the absence of acute embolic episodes (p=0.0007), higher cardiac index (p=0.01), lower mean Pra (p<0.0001), lower central disease score (p=0.03) and non-type 1 disease (p=0.01).
Differences of Clinical Phenotype in Female CTEPH Based on HLA Types
To identify the differences of clinical phenotype of female Tables 1,3 .
Values are mean±SD or n (%). Abbreviations see in
CTEPH based on HLA types, we compared the clinical characteristics of HLA-B*5201-positive and -negative females. As shown in Table 6 , HLA-B*5201-positive females had less history of DVT (13.5 vs 42.3%, p=0.0036) and less non-type 1 disease (13.3 vs 48%, p=0.02) compared with HLA-B*5201-negative females.
Discussion
The incidence of pulmonary thromboembolism in Japan in 2004 (4,106 patients) was much lower than in the USA (630,000). 20 The absence of factor V leiden and prothrombin mutation, and low lipid levels in the Japanese might be involved in the difference between Japanese and Caucasian populations with this disease. 21, 22 However, female predominance and a higher incidence ratio of chronic to acute pulmonary thromboembolism in Japan as compared to those in the USA were recently reported. [1] [2] [3] From an annual report in Japan, the total number of CTEPH patients in Japan was 800 in 2006. 23 It was reported that the risk of recurrent venous thromboembolism was higher in men than women, but the female-to-male ratio in CTEPH is 2.1 in Japan, much higher than that of 0.7 in the USA. 3, 7, 8 In addition, we previously reported that HLA-B*5201-positive patients with Japanese CTEPH were predominantly females and were unrelated to DVT. 11 The frequency of HLA-B*5201 among the normal population in Japan was reported to be 20%, much higher than 2% in western countries. [24] [25] [26] Then we considered that the HLA-B*5201-positive type indicates Japanese-specific CTEPH, and that HLA-B*5201-negative type could indicate CTEPH related to DVT, similar to Western countries.
We investigated whether the clinical phenotype in female CTEPH differs from male CTEPH, especially in the Japanese series.
Female patients were elderly and had less DVT, less acute embolic episodes, a higher cardiac index, lower mean Pra, lower PaO2, more peripheral thrombi and less improvement through surgery than males. When the patients were divided according to HLA-B*5201 status, in HLA-B*5201-positive patients, females showed less embolic episodes, higher cardiac index and lower mean Pra with lower operative mortality. In contrast, in HLA-B*5201-negative patients, females showed less embolic episodes and more peripheral thrombi, resulting in less improvement through surgery. This is the first report to reveal gender differences in the clinical characteristics of CTEPH, and that gender differences in the HLA-B*5201-positive type were dissimilar to those in HLA-B*5201-negative type.
Several issues need to be considered in the interpretation of these results. First, female CTEPH showed peripheral thrombi according to the central disease score and intraoperative classification. These findings were similar to those of Jamieson et al, who reported that females predominate in type 3 disease (distal segmental arteries only type). 10 When the patients were divided according to HLA-B*5201 status, only in HLA-B*5201-negative patients did females show more peripheral type than males, but in HLA-B*5201-positive patients such difference could not be observed. It remains uncertain why female CTEPH showed more of the peripheral type that in the USA as well as in HLA-B*5201-negative type in Japan. Although distal small DVT could induce peripheral type CTEPH, it is possible that peripheral pulmonary arteriopathy, similar to pulmonary arterial hypertension, in situ thrombosis might cause peripheral type CTEPH. 2 As shown in Table 6 , in females, the frequencies of non-type 1 in intra-operative classifications were significantly higher in HLA-B*5201-negative than in -positive type patients. We have already shown that the frequencies of HLA-B*5201 were higher in CTEPH with central predominant type. 10 It seems that the existence of HLA-B*5201 might be related to a more proximal location of thrombi only in females.
Second, female patients showed less history of DVT. However, there was no significant difference in DVT between males and females when the patients were divided by HLA-B*5201 status. Additionally, multiple regression analysis revealed that the HLA-B*5201-positive type significantly correlated with the absence of DVT, but female gender did not show significant correlation with DVT. It is likely that a significant correlation with female gender might be related to female predominance in the HLA-B*5201-positive type. Takayasu arteritis is epidemiologically known for its female predominance, and the association of HLA-B*5201 with this disease has been well documented in Japan. 13, 14, 27 Takayasu arteritis is a chronic vasculitis, mainly involving the aorta and its major branches, as well as the coronary and pulmonary arteries. 28 The frequency of HLA-B*5201 in CTEPH was similar to that reported in Takayasu arteritis. 27 We previously reported that the HLA-B*5201-positive type showed female predominance and was unrelated to DVT, and that this Japanese-specific type might include underdiagnosed pulmonary arteritis secondary to thrombi, although Takayasu arteritis was clinically excluded by CT angiographies. In our series, the frequency of HLA-B*5201-positive type (27.0%) in male CTEPH was not dissimilar to that in the normal Japanese population (20.0%), while that in female CTEPH (41.6%) was much higher. Only female CTEPH in HLA-B*5201-positive type could be a specific Japanese type unrelated to DVT, caused by underdiagnosed arteritis secondary to thrombi.
Third, univariate analysis showed that female patients had less history of acute embolic episode regardless of the existence of HLA-B*5201. The results obtained by multiple logistic regression also showed that acute embolic episode was influenced by gender more strongly than the existence of HLA-B*5201. The peripheral type of CTEPH and lower frequency of DVT might be related to less embolic episodes.
Fourth, female patients showed higher cardiac index and lower mean Pra, indicating preserved right ventricular function. Although preserved right ventricular function in females was significant only in HLA-B*5201-positive type, 2-way factorial ANOVA revealed that female gender had the main effect on higher cardiac index and lower mean Pra independent of the existence of HLA-B*5201. Several studies of the left ventricle have suggested that female gender is associated with more favorable myocardial adaptations to hemodynamic overload, including a better preserved contractile response and a greater adaptive hypertrophic reserve. [29] [30] [31] Our data for the right ventricle were consistent with these data. The use of diuretics did not differ between males and females (62.5 vs 62.7%, p=0.99). Only fifteen patients had systemic hypertension, with 3 of them taking an angiotensin converting enzyme inhibitor. Therefore, it is unlikely that such medications might have strong effects on gender difference in terms of right ventricular function.
Female patients had less heart disease compared with males. After excluding patients with heart disease, females still showed higher cardiac index and lower mean Pra. In addition, there was no significant differences in pulmonary capillary wedge pressure (7.3 vs 6.1 mmHg, p=0.83) between male and female CTEPH. Further studies on gender differences regarding right ventricular function will be needed.
Fifth, female patients showed higher postoperative PVR and a modest percentage decrease in PVR in all patients as well as in the HLA-B*5201-negative type. In contrast, the mortality of female patients was lower than that of males in only the HLA-B*5201-positive type despite similar postoperative PVR and percentage decrease in PVR. The peripheral type of emboli in females could be related to less improvement using surgery in all patients as well as in the HLA-B*5201-negative type. In contrast, it is likely that better right ventricular function in females contributes to lower mortality in HLA-B*5201-positive type. We previously reported that the female HLA-B*5201-positive type had a tendency to be the central predominant type. 11 In the present study, HLA-B*5201-positive females showed more type 1 disease compared with HLA-B*5201-negative females, although there was no significant difference in central disease score. More type 1 disease in HLA-B*5201-positive females could be related to lower mortality.
Finally, the present study is based on the results from a single institution, and the number of patients in each group subcategorized according to gender and HLA type was small. Nonetheless, it will be important to manage patients while taking into account gender differences and HLA type. Larger studies are needed to confirm the relationship of gender difference and clinical phenotype.
In conclusion, to our knowledge, this is the first study to report that clinical phenotype in female CTEPH differed from that in males, and that gender differences in HLA-B* 5201-positive type were dissimilar to those in HLA-B*5201-negative type.
